* denotes a publication that resulted from CTD2 intra-Network collaborations
Researchers identify a specific dependency on BRCA1 and members of the ubiquitin pathway in cyclin E1 amplified tumors and propose a unique therapeutic strategy with bortezomib.
Researchers identify STF-118804 as a specific inhibitor of nicotinamide phosphoribosyl transferase (NAMPT), which improves survival in high-risk acute lymphoblastic leukemia, and targets leukemia stem cells.
Researchers evaluate xenografts established in NOD/scid/IL2Rγ-null mice from the primary and metastatic tumors of 27 patients with colorectal cancer (CRC) to assess how faithfully they recapitulated the transcriptional profile of their parental tumors.
Researchers demonstrate that transient inhibition of eIF4E protects against cyclophosphamide-induced alopecia at the organismal level.
The results provide novel insights into the synthetic lethal nature of α5-GABAA receptor activation in MYC-driven/Group 3 medulloblastomas and propose targeting it as a novel strategy.
We have applied parallel screening of chemical and genetic perturbations within a panel of molecularly annotated non-small-cell lung cancer lines to identify intervention opportunities tightly linked to molecular response indicators predictive of target sensitivity.
Researchers present a cancer driver annotation (CanDrA) tool that predicts missense driver mutations based on a set of 95 structural and evolutionary features computed by over 10 functional prediction algorithms.
Researchers accrued a library of natural products and performed a screen to identify molecular targets.
Investigators use a high-throughput assay to identify genomic predictors of radiation sensitivity